All In Biotech

Drug Trial Radar · NCT04115410

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Last checked: Nov 19, 2026Latest source record: May 28, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

4,724

Planned (sponsor's estimate)

Start

Jul 1, 2020

Primary completion

Sep 23, 2021

Study completion Dec 31, 2021

Sponsor

Lead sponsor
Sungkyunkwan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ministry of Food and Drug Safety, Korea
First posted
Oct 4, 2019

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of our study is to assess the risk of immune-related adverse events associated with PD-1 inhibitors use compared to standard chemotherapy use in patients with non small cell lung cancer, using nationwide healthcare database.

Conditions

  • Carcinoma, Non-Small-Cell Lung
  • Immune-Related Adverse Events

Interventions

  • PD-1 inhibitorDrug

    PD-1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer. The investigators will include nivolumab, pembrolizumab, and atezolizumab as PD-1 inhibitors as these drugs are reimbursed by health authority of South Korea.

  • Chemotherapy Drugs, CancerDrug

    Chemotherapy is a type of pharmacotherapy for cancer, that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen. The investigators will include cytotoxic chemotherapy and tyrosine kinase inhibitors (epidermal growth cell receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hazard ratio for immune-related adverse eventsTime frame: August 2017 to December 2018

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.